ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
Year: 2018
Type: article
Institutions: Medizinische Hochschule Brandenburg Theodor Fontane, Universitätsklinikum Brandenburg an der Havel, FundeSalud, University of Zurich, University Hospital Zurich, Instituto de Salud Carlos III, Red Espanola de Investigacion en Patologia Infecciosa, Hospital Universitario Ramón y Cajal, Leiden University Medical Center, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, University of Insubria, Ospedale di Circolo e Fondazione Macchi
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: biologic therapy, tyrosine kinase inhibitors, mTOR inhibitors, BCR-ABL tyrosine kinase inhibitors, dasatinib, cytomegalovirus reactivation, HBV reactivation, BRAF/MEK inhibitors, ibrutinib, Pneumocystis carinii pneumonia, progressive multifocal leukoencephalopathy, PI3K inhibitors, idelalisib, venetoclax, BCL-2 inhibitor, JAK inhibitors, opportunistic infections, infection control, latent tuberculosis infection, cancer patients
Open Access status: bronze
OpenAlex ID: W2788138754
